Mainz Biomed Past Earnings Performance

Past criteria checks 0/6

Mainz Biomed's earnings have been declining at an average annual rate of -32.6%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been growing at an average rate of 16.2% per year.

Key information

-32.6%

Earnings growth rate

-21.6%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate16.2%
Return on equityn/a
Net Margin-2,453.9%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Mainz Biomed GAAP EPS of -$0.91, revenue of $0.24M beats by $0.14M

Sep 07

Mainz Biomed stock rises 22% on launch of colorectal cancer test in Italy, UAE

Aug 16

Mainz Biomed: Sharp Appreciation In Value Since IPO

Jan 26

Revenue & Expenses Breakdown

How Mainz Biomed makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqCM:MYNZ Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 241-23157
31 Mar 241-25179
31 Dec 231-261810
30 Sep 231-291910
30 Jun 231-29209
31 Mar 231-27226
31 Dec 221-26225
30 Sep 220-24212
30 Jun 220-24211
31 Mar 221-17151
31 Dec 211-1290
31 Dec 200-100
31 Dec 190-110

Quality Earnings: MYNZ is currently unprofitable.

Growing Profit Margin: MYNZ is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: MYNZ is unprofitable, and losses have increased over the past 5 years at a rate of 32.6% per year.

Accelerating Growth: Unable to compare MYNZ's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MYNZ is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).


Return on Equity

High ROE: MYNZ's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies